Series E



Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders at the right place and the right time. MeMeds interdisciplinary team has decades of experience and a proven track record in diverse fields including molecular immunology, informatics, clinical infectious diseases and in vitro diagnostics.

Kfir OvedCTO
Eran EdenCEO

Eli OpperBoard Advisor
Itamar ShalitBoard Advisor
Louis BontBoard Advisor
Paul FeiginBoard Advisor
Yoram ReiterBoard Advisor

RoundDate AnnouncedInvestors
MeMed raises $93 millionJanuary 10, 202211
MeMed raises $2.8 Million GrantNovember 13, 20191
MeMed raises $70 millionSeptember 30, 20189
Memed raises $30 millionSeptember 19, 20173

Investor NameInvestor TypeAUM ($)
Caesarea Medical HoldingsCompany0
Clal InsuranceCompany0
Horizons VenturesVenture Capital0
Jaan Tallinn0
La Maison PartnersVenture Capital0
Li Ka-Shing0
Phoenix Insurance CompanyCompany60,000,000,000
Ping An Global Voyager FundCorporate Venture Capital0
Poalim Capital MarketsInvestment Firm0
Poalim Equity0
Shavit CapitalPrivate Equity400,000,000
Social CapitalVenture Capital1,495,000,000
Touchwood CapitalFamily Office0
Union Tech VenturesCorporate Venture Capital0
Western Technology Investments0

TitleDate Announced
MeMed BV FDASeptember 22, 2021
MeMed Covid-19 SeverityJuly 27, 2021
MeMedMeMed KeyCEJune 2, 2020
MeMedMeMed BVCEJune 2, 2020


Our pipeline of AI-based diagnostics addresses key clinical and medical challenges in infectious diseases and inflammatory disorders. Using low and high-throughput molecular measurements, the application of bioinformatics and machine learning approaches, we’ve identified biomarkers that are key players in the body’s response to different disease states. These biomarkers and algorithms are now being integrated into immunological fingerprints for decoding multiple disease states.

Sign up for free

  • Save profiles to your list
  • Basic search functionality